

Christopher Moore

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4623198/publications.pdf>

Version: 2024-02-01

7
papers

491
citations

1307594

7
h-index

1720034

7
g-index

9
all docs

9
docs citations

9
times ranked

893
citing authors

| # | ARTICLE | IF | CITATIONS |
|---|---|------|-----------|
| 1 | Repurposed floxacins targeting RSK4 prevent chemoresistance and metastasis in lung and bladder cancer. <i>Science Translational Medicine</i> , 2021, 13, . | 12.4 | 19 |
| 2 | Characterisation of tumour microenvironment remodelling following oncogene inhibition in preclinical studies with imaging mass cytometry. <i>Nature Communications</i> , 2021, 12, 5906. | 12.8 | 36 |
| 3 | Combined targeting of G proteinâ€coupled receptor and <sc>EGF</sc> receptor signaling overcomes resistance to <sc>PI</sc> 3K pathway inhibitors in <sc>PTEN</sc> â€null triple negative breast cancer. <i>EMBO Molecular Medicine</i> , 2020, 12, e11987. | 6.9 | 17 |
| 4 | RAC1P29S Induces a Mesenchymal Phenotypic Switch via Serum Response Factor to Promote Melanoma Development and Therapy Resistance. <i>Cancer Cell</i> , 2019, 36, 68-83.e9. | 16.8 | 104 |
| 5 | <i>ATMIN</i> Is a Tumor Suppressor Gene in Lung Adenocarcinoma. <i>Cancer Research</i> , 2019, 79, 5159-5166. | 0.9 | 10 |
| 6 | Development of combination therapies to maximize the impact of KRAS-G12C inhibitors in lung cancer. <i>Science Translational Medicine</i> , 2019, 11, . | 12.4 | 150 |
| 7 | Requirement for Interaction of PI3-Kinase p110Î± with RAS in Lung Tumor Maintenance. <i>Cancer Cell</i> , 2013, 24, 617-630. | 16.8 | 148 |